Structured evidence table for Peppermint Irritable Bowel Syndrome Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Peppermint Irritable Bowel Syndrome Randomized Trial | Evidence from recent systematic reviews and meta-analyses consistently indicates that peppermint oil is the most effective botanical agent, particularly for reducing abdominal pain and overall IBS symptom severity. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Irritable Bowel Syndrome Randomized Trial | The aim of this review is to summarize, compare, and critically evaluate all plant extracts studied for the prevention and treatment of IBS, integrating mechanistic pathways, clinical evidence, and current international guideline recommendations to clarify their therapeutic relevance for clinical practice. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Irritable Bowel Syndrome Randomized Trial | Irritable Bowel Syndrome (IBS) affects 4-15% of the global population, and the limited efficacy of existing pharmacologic therapies has driven growing interest in plant-based therapeutic options among both patients and clinicians. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Irritable Bowel Syndrome Randomized Trial | A comprehensive assessment of all plant extracts investigated in IBS is therefore essential, given the limited effectiveness of conventional treatments and the increasing interest in complementary approaches. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Irritable Bowel Syndrome Randomized Trial | Abdominal pain must be associated with two or more of the following: defecation, change in stool frequency, or change in stool form (Rome [Foundation] IV criteria;). | 4 | Ladewski Amy M. (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations |
| Peppermint Irritable Bowel Syndrome Randomized Trial | The emphasis that NPs and PAs place on holistic, patient-centered care provides increased opportunities for education and counseling, and patients with disorders of gut–brain interaction, such as IBS, would benefit from a collaborative treatment approach that validates their experiences and addresses their most bothersome symptoms (;;). | 4 | Ladewski Amy M. (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations |
| Peppermint Irritable Bowel Syndrome Randomized Trial | He reported no evidence of rectal bleeding or unintentional weight loss and had no known family history of colorectal cancer, inflammatory bowel disease (IBD), or other GI conditions. | 4 | Ladewski Amy M. (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations |
| Peppermint Irritable Bowel Syndrome Randomized Trial | This condition is characterized by recurrent abdominal pain occurring at least 1 day per week, on average, during the previous 3 months, with symptom onset at least 6 months before diagnosis. | 4 | Ladewski Amy M. (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations |
Source documents